Sartorius AG
XETRA:SRT
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
168
288
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one SRT stock under the Base Case scenario is 188.65 EUR. Compared to the current market price of 175.8 EUR, Sartorius AG is Undervalued by 7%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Sartorius AG
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for SRT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Sartorius AG is a globally recognized leader in the biopharmaceutical and laboratory equipment sectors, dedicated to enhancing the efficiency of research and production processes. Founded in 1870 and headquartered in Göttingen, Germany, this innovative company provides a comprehensive range of products and services that support the life sciences industry—from advanced laboratory instruments to high-quality access materials for biopharmaceutical manufacturing. As the demand for biotechnological solutions continues to rise, particularly in response to global health challenges, Sartorius stands out by offering critical tools and technologies, positioning itself at the forefront of a thriving ma...
Sartorius AG is a globally recognized leader in the biopharmaceutical and laboratory equipment sectors, dedicated to enhancing the efficiency of research and production processes. Founded in 1870 and headquartered in Göttingen, Germany, this innovative company provides a comprehensive range of products and services that support the life sciences industry—from advanced laboratory instruments to high-quality access materials for biopharmaceutical manufacturing. As the demand for biotechnological solutions continues to rise, particularly in response to global health challenges, Sartorius stands out by offering critical tools and technologies, positioning itself at the forefront of a thriving market with sustainable growth potential.
Investors will find Sartorius particularly attractive due to its robust business model, marked by significant investments in research and development that fuel continuous innovation. The company has experienced impressive revenue growth, bolstered by strategic acquisitions that expand its technological capabilities and market reach. With a committed focus on sustainability and efficiency, Sartorius not only drives profitability but also aligns with the growing investor preference for socially responsible enterprises. As healthcare demands increase and the biopharmaceutical industry evolves, Sartorius AG offers a compelling investment opportunity characterized by a strong market position, strategic foresight, and a commitment to improving human health across the globe.
Sartorius AG is a globally recognized pharmaceutical and laboratory equipment supplier. The company primarily operates in two core business segments:
-
Bioprocess Solutions:
- This segment focuses on providing products and services for the development and production of biopharmaceuticals. This includes equipment and consumables used in cell culture, fermentation, filtration, purification, and formulation processes. Key offerings include single-use technologies, bioreactors, and various laboratory analyzers. Sartorius aims to support biopharmaceutical companies in their workflow efficiency and cost-effectiveness.
-
Laboratory Products & Services:
- This segment caters to laboratories in the pharmaceutical, biotechnology, and food industries by offering a wide range of instruments, consumables, and services for laboratory processes. This includes balances, pipettes, lab water systems, and other analytical instruments. Sartorius also provides software solutions for laboratory management and data analysis.
Both segments emphasize innovation, quality, and regulatory compliance, essential for meeting the stringent requirements of the life sciences industry. Sartorius AG's commitment to sustainable practices and digital transformation also reflects in its product offerings, enhancing operational efficiency for its customers.
Sartorius AG, a global pharmaceutical and laboratory equipment supplier, possesses several unique competitive advantages that set it apart from its rivals in the bioprocessing and life sciences sectors:
-
Strong Brand Reputation: Sartorius has established a trusted brand recognized for quality and reliability in bioprocessing and laboratory equipment. This strong reputation enhances customer loyalty and facilitates new client acquisitions.
-
Advanced Technological Innovation: Sartorius invests heavily in research and development, enabling the company to offer cutting-edge products and solutions. This focus on innovation leads to unique product features and enhanced performance, giving Sartorius a technological edge over competitors.
-
Comprehensive Product Portfolio: Sartorius provides a broad range of products and services that cater to various stages of drug development and manufacturing processes, from laboratory instruments to bioprocessing solutions. This all-encompassing portfolio allows for cross-selling opportunities and makes Sartorius a one-stop shop for customers.
-
Customer-Centric Approach: The company emphasizes strong customer relationships and tailored solutions. Sartorius often collaborates closely with clients to meet their specific needs, fostering long-term partnerships.
-
Global Presence with Local Expertise: Sartorius operates in numerous countries, providing them with a global reach while maintaining local expertise. This allows the company to navigate regional regulations and market dynamics effectively, providing customized solutions that address local market demands.
-
Strong Financial Performance and Stability: With a solid financial foundation, Sartorius can invest in growth opportunities, research, and strategic acquisitions, which further strengthens its market position.
-
Commitment to Sustainability: Sartorius actively integrates sustainability into its operations and product offerings, resonating with the growing market segment that prioritizes environmentally friendly practices. This commitment can provide a competitive advantage in increasingly eco-conscious markets.
-
Robust Supply Chain and Manufacturing Capabilities: The company has optimized its supply chain and manufacturing processes to ensure efficiency and reliability. This enables Sartorius to meet customer demands promptly while maintaining quality standards.
Overall, through innovation, a strong product portfolio, customer focus, and a commitment to sustainability, Sartorius AG differentiates itself in a competitive marketplace, positioning it well for long-term success.
Sartorius AG, as a global pharmaceutical and laboratory equipment supplier, faces several risks and challenges in the near future:
-
Market Volatility: Fluctuations in the global economy can impact demand for biotechnology and pharmaceutical products, affecting Sartorius's sales.
-
Regulatory Compliance: The biopharmaceutical industry is subject to strict regulations. Changes in regulations or compliance requirements could increase operational costs or slow down product time-to-market.
-
Supply Chain Disruptions: Global events, such as pandemics or geopolitical tensions, may disrupt supply chains, leading to delays in production and delivery.
-
Technological Advancements: Rapid innovation in biotechnology may require Sartorius to continuously adapt and develop new technologies. Failing to keep pace could lead to loss of market share.
-
Competition: Intense competition from both established players and new entrants in biotechnology and laboratory services could impact Sartorius's pricing power and market share.
-
Currency Fluctuations: As a multinational company, Sartorius is exposed to foreign exchange risks, which could affect profitability, especially when operating in multiple currencies.
-
Mergers and Acquisitions: Integration challenges or cultural mismatches from recent acquisitions may hinder operational efficiency and expected synergies.
-
Talent Acquisition and Retention: The demand for skilled professionals in biotech is increasing. Sartorius may face challenges in attracting and retaining top talent and expertise necessary for innovation.
-
Environmental Concerns: Increasing scrutiny on sustainability practices may pressure the company to enhance its environmental policies and processes, potentially leading to higher costs.
-
Customer Concentration Risks: If a significant portion of Sartorius's revenues comes from a limited number of customers, losing any of these key clients could significantly impact revenues.
Addressing these challenges requires effective risk management strategies and ongoing commitment to innovation and operational excellence.
Revenue & Expenses Breakdown
Sartorius AG
Balance Sheet Decomposition
Sartorius AG
Current Assets | 2B |
Cash & Short-Term Investments | 611m |
Receivables | 393m |
Other Current Assets | 965.1m |
Non-Current Assets | 7.8B |
Long-Term Investments | 103.3m |
PP&E | 2.2B |
Intangibles | 5.4B |
Other Non-Current Assets | 85.9m |
Current Liabilities | 977m |
Accounts Payable | 226.3m |
Accrued Liabilities | 125.1m |
Other Current Liabilities | 625.6m |
Non-Current Liabilities | 6.1B |
Long-Term Debt | 4.4B |
Other Non-Current Liabilities | 1.7B |
Earnings Waterfall
Sartorius AG
Revenue
|
3.3B
EUR
|
Cost of Revenue
|
-1.9B
EUR
|
Gross Profit
|
1.5B
EUR
|
Operating Expenses
|
-1B
EUR
|
Operating Income
|
416.7m
EUR
|
Other Expenses
|
-333.5m
EUR
|
Net Income
|
83.2m
EUR
|
Free Cash Flow Analysis
Sartorius AG
EUR | |
Free Cash Flow | EUR |
In the first quarter of 2024, the company saw a mixed performance. Order intake grew by almost 10%, driven mainly by the Americas, while sales revenue decreased by 7.5% compared to the strong numbers seen in the previous year. China showed the weakest performance in both order intake and sales. Profitability remained robust with an EBITDA margin of 28.6%. The company maintains its full-year guidance, projecting mid- to high single-digit sales revenue growth and an EBITDA margin slightly above 30% by year-end. Order intake for consumables showed strong double-digit growth, while equipment sales were muted.
What is Earnings Call?
SRT Profitability Score
Profitability Due Diligence
Sartorius AG's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
Score
Sartorius AG's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
SRT Solvency Score
Solvency Due Diligence
Sartorius AG's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Score
Sartorius AG's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SRT Price Targets Summary
Sartorius AG
According to Wall Street analysts, the average 1-year price target for SRT is 296.48 EUR with a low forecast of 214.12 EUR and a high forecast of 367.5 EUR.
Dividends
Current shareholder yield for SRT is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
SRT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Sartorius AG is a DE-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Goettingen, Niedersachsen and currently employs 15,051 full-time employees. Sartorius AG is a Germany-based supplier of pharmaceutical and laboratory equipment. The company operates through two segments: Bioprocess Solutions and Lab Products and Services. The Bioprocess Solutions segment offers integrated solutions for biopharmaceutical manufacture, such as filters for sterilization of biopharmaceutical media, single-use bags for cell cultivation and storage of biopharmaceuticals, membrane adsorbers for purification in bioprocesses, and filter technology for clarification, among others. The Lab Products and Services segment provides instruments, consumables and services for laboratories, including laboratory balances, laboratory water systems for storage of purified water, electronic pipettes, filter systems for sample preparation and membrane filter systems for sterility testing of parenterals.
Contact
IPO
Employees
Officers
The intrinsic value of one SRT stock under the Base Case scenario is 188.65 EUR.
Compared to the current market price of 175.8 EUR, Sartorius AG is Undervalued by 7%.